Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.

Lazaryan A, Dolan M, Zhang MJ, Wang HL, Kharfan-Dabaja MA, Marks DI, Bejanyan N, Copelan E, Majhail NS, Waller EK, Chao N, Prestidge T, Nishihori T, Kebriaei P, Inamoto Y, Hamilton B, Hashmi SK, Kamble RT, Bacher U, Hildebrandt GC, Stiff PJ, McGuirk J, Aldoss I, Beitinjaneh AM, Muffly L, Vij R, Olsson RF, Byrne M, Schultz KR, Aljurf M, Seftel M, Savoie ML, Savani BN, Verdonck LF, Cairo MS, Hossain N, Bhatt VR, Frangoul HA, Abdel-Azim H, Al Malki M, Munker R, Rizzieri D, Khera N, Nakamura R, Ringdén O, van der Poel M, Murthy HS, Liu H, Mori S, De Oliveira S, Bolaños-Meade J, Elsawy M, Barba P, Nathan S, George B, Pawarode A, Grunwald M, Agrawal V, Wang Y, Assal A, Castillo Caro P, Kuwatsuka Y, Seo S, Ustun C, Politikos I, Lazarus HM, Saber W, Sandmaier BM, De Lima M, Litzow M, Bachanova V, Weisdorf D; Acute Leukemia Committee of the CIBMTR.

Haematologica. 2019 Sep 26. pii: haematol.2019.220756. doi: 10.3324/haematol.2019.220756. [Epub ahead of print]

2.

Autologous stem cell transfusions on multiple days in patients with multiple myeloma-Does it matter?

Moser S, Bacher U, Jeker B, Mansouri Taleghani B, Betticher D, Ruefer A, Egger T, Novak U, Pabst T.

Hematol Oncol. 2019 Sep 4. doi: 10.1002/hon.2673. [Epub ahead of print] No abstract available.

PMID:
31483507
3.

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.

Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR.

Clin Cancer Res. 2019 Aug 15;25(16):5143-5155. doi: 10.1158/1078-0432.CCR-18-3988. Epub 2019 Jun 28.

PMID:
31253630
4.

Molecular minimal residual disease negativity and decreased stem cell mobilization potential predict excellent outcome after autologous transplant in NPM1 mutant acute myeloid leukemia.

De Santiago de Benito A, Jeker B, Gfeller E, Porret N, Banz Y, Novak U, Bacher U, Pabst T.

Haematologica. 2019 May 23. pii: haematol.2019.216457. doi: 10.3324/haematol.2019.216457. [Epub ahead of print]

5.

Clinical value of molecular MRD monitoring by next-generation sequencing in patients with IDH2 mutated AML.

Shumilov E, Flach J, Joncourt R, Porret N, Wiedemann G, Novak U, Gfeller E, Jeker B, Amstutz U, Pabst T, Bacher U.

Leuk Lymphoma. 2019 Oct;60(10):2588-2590. doi: 10.1080/10428194.2019.1585838. Epub 2019 Apr 18. No abstract available.

PMID:
30998101
6.

Improved survival rates of AML patients following admission to the intensive care unit.

Fassbind P, Jeker B, Mueller BU, Bacher U, Zimmerli S, Endrich O, Gahl B, Novak U, Pabst T.

Leuk Lymphoma. 2019 Oct;60(10):2423-2431. doi: 10.1080/10428194.2019.1594213. Epub 2019 Apr 3.

PMID:
30943056
7.

High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients.

Prediletto I, Farag SA, Bacher U, Jeker B, Mansouri Taleghani B, Brégy R, Zander T, Betticher D, Egger T, Novak U, Pabst T.

Bone Marrow Transplant. 2019 Mar 19. doi: 10.1038/s41409-019-0508-2. [Epub ahead of print] No abstract available.

PMID:
30890768
8.

Critical evaluation of current molecular MRD strategies including NGS for the management of AML patients with multiple mutations.

Shumilov E, Flach J, Joncourt R, Porret N, Wiedemann G, Angelillo-Scherrer A, Trümper L, Fiedler M, Jeker B, Amstutz U, Pabst T, Bacher U.

Hematol Oncol. 2019 Aug;37(3):319-322. doi: 10.1002/hon.2603. Epub 2019 Mar 28. No abstract available.

PMID:
30843248
9.

Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma.

Amsler IG, Jeker B, Mansouri Taleghani B, Bacher U, Betticher D, Egger T, Zander T, Luethi JM, Novak U, Pabst T.

Leuk Lymphoma. 2019 Feb;60(2):511-514. doi: 10.1080/10428194.2018.1473577. Epub 2019 Jan 8. No abstract available.

PMID:
30616438
10.

Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use.

Bacher U, Shumilov E, Flach J, Porret N, Joncourt R, Wiedemann G, Fiedler M, Novak U, Amstutz U, Pabst T.

Blood Cancer J. 2018 Nov 12;8(11):113. doi: 10.1038/s41408-018-0148-6. Review.

11.

Autologous Transplantation for Older Adults with AML.

Mueller BU, Seipel K, Bacher U, Pabst T.

Cancers (Basel). 2018 Sep 19;10(9). pii: E340. doi: 10.3390/cancers10090340. Review.

12.

Iron overload is correlated with impaired autologous stem cell mobilization and survival in acute myeloid leukemia.

Alva LC, Bacher U, Seipel K, Mansouri Taleghani B, Mueller BU, Novak U, Pabst T.

Transfusion. 2018 Oct;58(10):2365-2373. doi: 10.1111/trf.14895. Epub 2018 Sep 10.

PMID:
30203418
13.

Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients.

Farag S, Jeker B, Bacher U, Mansouri Taleghani B, Mueller BU, Novak U, Pabst T.

Hematol Oncol. 2018 Oct;36(4):671-678. doi: 10.1002/hon.2546. Epub 2018 Sep 11.

PMID:
30110717
14.

Pitfalls in the molecular follow up of NPM1 mutant acute myeloid leukemia.

Bacher U, Porret N, Joncourt R, Sanz J, Aliu N, Wiedemann G, Jeker B, Banz Y, Pabst T.

Haematologica. 2018 Oct;103(10):e486-e488. doi: 10.3324/haematol.2018.192104. Epub 2018 Jun 14. No abstract available.

15.

Adverse outcome of AML with aberrant CD16 and CD56 NK cell marker expression.

Junge A, Bacher U, Mueller BU, Keller P, Solenthaler M, Pabst T.

Hematol Oncol. 2018 Jun 3. doi: 10.1002/hon.2516. [Epub ahead of print]

PMID:
29862539
16.

Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology.

Shumilov E, Flach J, Pabst T, Fiedler M, Angelillo-Scherrer A, Trümper L, Joncourt R, Kohlmann A, Bacher U.

Crit Rev Oncol Hematol. 2018 Jun;126:64-79. doi: 10.1016/j.critrevonc.2018.03.020. Epub 2018 Mar 29. Review.

PMID:
29759569
17.

Current status and trends in the diagnostics of AML and MDS.

Shumilov E, Flach J, Kohlmann A, Banz Y, Bonadies N, Fiedler M, Pabst T, Bacher U.

Blood Rev. 2018 Nov;32(6):508-519. doi: 10.1016/j.blre.2018.04.008. Epub 2018 Apr 27. Review.

PMID:
29728319
18.

Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.

Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A, Bolaños-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S, Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN, Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, Hamadani M.

Cancer. 2018 Jun 15;124(12):2541-2551. doi: 10.1002/cncr.31374. Epub 2018 Apr 12.

19.

Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders.

Schanz J, Cevik N, Fonatsch C, Braulke F, Shirneshan K, Bacher U, Haase D.

Blood Cancer J. 2018 Mar 7;8(3):28. doi: 10.1038/s41408-018-0061-z.

20.

In Situ Validation of the Endothelial Cell Receptor GRP78 in a Case of Rhinocerebral Mucormycosis.

Shumilov E, Bacher U, Perske C, Mohr A, Eiffert H, Hasenkamp J, Trümper L, Wulf GG, Ströbel P, Ibrahim AS, Venkataramani V.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00172-18. doi: 10.1128/AAC.00172-18. Print 2018 May. No abstract available.

21.

Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.

Gössi U, Jeker B, Mansouri Taleghani B, Bacher U, Novak U, Betticher D, Egger T, Zander T, Pabst T.

Hematol Oncol. 2018 Apr;36(2):436-444. doi: 10.1002/hon.2490. Epub 2018 Jan 24.

PMID:
29363149
22.

Coincidence of 5q deletion and the JAK2V617F mutation: report of two patients with overlapping myelodysplastic and myeloproliferative features and review of the literature.

Bürki S, Shumilov E, Bonadies N, Flach J, Legros M, Banz Y, Oppliger-Leibundgut E, Fiedler M, Angelillo-Scherrer A, Rovo A, Bacher U.

Leuk Lymphoma. 2018 Sep;59(9):2233-2237. doi: 10.1080/10428194.2017.1416367. Epub 2018 Jan 3. Review. No abstract available.

PMID:
29295644
23.

Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens.

Oyekunle A, Shumilov E, Kostrewa P, Burchert A, Trümper L, Wuchter P, Wulf G, Bacher U, Kröger N.

Biol Blood Marrow Transplant. 2018 Feb;24(2):276-281. doi: 10.1016/j.bbmt.2017.10.008. Epub 2017 Oct 13.

24.

Impact of molecular residual disease post allografting in myelofibrosis patients.

Wolschke C, Badbaran A, Zabelina T, Christopeit M, Ayuk F, Triviai I, Zander A, Alchalby H, Bacher U, Fehse B, Kröger N.

Bone Marrow Transplant. 2017 Nov;52(11):1526-1529. doi: 10.1038/bmt.2017.157. Epub 2017 Jul 17.

PMID:
28714945
25.

Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis.

Thoennissen GB, Görlich D, Bacher U, Aufenberg T, Hüsken AC, Hansmeier AA, Evers G, Mikesch JH, Fritz F, Bokemeyer C, Müller-Tidow C, Stelljes M, Mesters RM, Krug U, Kropff MH, Thoennissen NH, Berdel WE.

Acta Haematol. 2017;137(3):163-172. doi: 10.1159/000463534. Epub 2017 Apr 12.

26.

Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.

Braulke F, Schulz X, Germing U, Schuler E, Platzbecker U, Nolte F, Hofmann WK, Giagounidis A, Götze K, Lübbert M, Schlenk RF, Schanz J, Bacher U, Ganser A, Büsche G, Letsch A, Schafhausen P, Bug G, Brümmendorf TH, Haas R, Trümper L, Shirneshan K, Haase D.

Ann Hematol. 2017 Jun;96(6):887-894. doi: 10.1007/s00277-017-2983-0. Epub 2017 Apr 3.

PMID:
28374162
27.

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.

Gerds AT, Woo Ahn K, Hu ZH, Abdel-Azim H, Akpek G, Aljurf M, Ballen KK, Beitinjaneh A, Bacher U, Cahn JY, Chhabra S, Cutler C, Daly A, DeFilipp Z, Gale RP, Gergis U, Grunwald MR, Hale GA, Hamilton BK, Jagasia M, Kamble RT, Kindwall-Keller T, Nishihori T, Olsson RF, Ramanathan M, Saad AA, Solh M, Ustun C, Valcárcel D, Warlick E, Wirk BM, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W.

Biol Blood Marrow Transplant. 2017 Jun;23(6):971-979. doi: 10.1016/j.bbmt.2017.03.014. Epub 2017 Mar 10.

28.

Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.

Michelis FV, Gupta V, Zhang MJ, Wang HL, Aljurf M, Bacher U, Beitinjaneh A, Chen YB, DeFilipp Z, Gale RP, Kebriaei P, Kharfan-Dabaja M, Lazarus HM, Nishihori T, Olsson RF, Oran B, Rashidi A, Rizzieri DA, Tallman MS, de Lima M, Khoury HJ, Sandmaier BM, Weisdorf D, Saber W; Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research, aresearch collaboration between the National Marrow Donor Program/Be the Match Registry and theMedicalCollegeofWisconsin.

Cancer. 2017 Jun 1;123(11):2035-2042. doi: 10.1002/cncr.30567. Epub 2017 Jan 24.

29.

Intestinal Pneumatosis Associated with Tuberculosis after Allogeneic Hematopoietic Stem Cell Transplantation.

Venkataramani V, Seif Amir Hosseini A, Schulze MH, Trümper L, Wulf G, Bacher U, Jung W.

Acta Haematol. 2017;137(1):51-54. doi: 10.1159/000452436. Epub 2016 Dec 7.

PMID:
27923223
30.
31.

Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.

Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, Hamadani M.

J Clin Oncol. 2016 Sep 10;34(26):3141-9. doi: 10.1200/JCO.2015.66.3476. Epub 2016 Jun 6.

32.

Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

Shaffer BC, Ahn KW, Hu ZH, Nishihori T, Malone AK, Valcárcel D, Grunwald MR, Bacher U, Hamilton B, Kharfan-Dabaja MA, Saad A, Cutler C, Warlick E, Reshef R, Wirk BM, Sabloff M, Fasan O, Gerds A, Marks D, Olsson R, Wood WA, Costa LJ, Miller AM, Cortes J, Daly A, Kindwall-Keller TL, Kamble R, Rizzieri DA, Cahn JY, Gale RP, William B, Litzow M, Wiernik PH, Liesveld J, Savani BN, Vij R, Ustun C, Copelan E, Popat U, Kalaycio M, Maziarz R, Alyea E, Sobecks R, Pavletic S, Tallman M, Saber W.

J Clin Oncol. 2016 Jun 1;34(16):1864-71. doi: 10.1200/JCO.2015.65.0515. Epub 2016 Apr 4.

33.

A transplant "immunome" screening platform defines a targetable epitope fingerprint of multiple myeloma.

Schieferdecker A, Oberle A, Thiele B, Hofmann F, Göthel M, Miethe S, Hust M, Braig F, Voigt M, von Pein UM, Koch-Nolte F, Haag F, Alawi M, Indenbirken D, Grundhoff A, Bokemeyer C, Bacher U, Kröger N, Binder M.

Blood. 2016 Jun 23;127(25):3202-14. doi: 10.1182/blood-2015-10-676536. Epub 2016 Mar 31.

PMID:
27034429
34.

Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation.

Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda A, Smith SM, Hamadani M.

Br J Haematol. 2016 Jul;174(2):235-48. doi: 10.1111/bjh.14046. Epub 2016 Mar 15.

35.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis.

Chaudhury S, Sparapani R, Hu ZH, Nishihori T, Abdel-Azim H, Malone A, Olsson R, Hamadani M, Daly A, Bacher U, Wirk BM, Kamble RT, Gale RP, Wood WA, Hale G, Wiernik PH, Hashmi SK, Marks D, Ustun C, Munker R, Savani BN, Alyea E, Popat U, Sobecks R, Kalaycio M, Maziarz R, Hijiya N, Saber W.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1056-1064. doi: 10.1016/j.bbmt.2016.02.015. Epub 2016 Mar 8.

36.

Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib.

Shumilov E, Wulf G, Ströbel P, Hasenkamp J, Hellige N, Bleckmann A, Haase D, Braulke F, Jung W, Schanz J, Binder M, Trümper L, Bacher U.

Leuk Lymphoma. 2016 Oct;57(10):2476-80. doi: 10.3109/10428194.2016.1151510. Epub 2016 Feb 25. No abstract available.

PMID:
26916814
37.

Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).

Schuler E, Giagounidis A, Haase D, Shirneshan K, Büsche G, Platzbecker U, Nolte F, Götze K, Schlenk RF, Ganser A, Letsch A, Braulke F, Lübbert M, Bug G, Schafhausen P, Bacher U, Gattermann N, Wulfert M, Haas R, Germing U.

Leukemia. 2016 Jul;30(7):1580-2. doi: 10.1038/leu.2015.340. Epub 2015 Dec 15. No abstract available.

PMID:
26668126
38.

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma.

Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger NM, Hari PN, Ku GH, Ayala E, Chen AI, Chen YB, Cohen JB, Freytes CO, Gale RP, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Martino R, Mussetti A, Savani BN, Schouten HC, Usmani SZ, Wiernik PH, Wirk B, Smith SM, Sureda A, Hamadani M.

Bone Marrow Transplant. 2016 Jan;51(1):58-66. doi: 10.1038/bmt.2015.223. Epub 2015 Oct 5.

39.

Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group.

Braulke F, Müller-Thomas C, Götze K, Platzbecker U, Germing U, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Hildebrandt B, Aul C, Stauder R, Valent P, Fonatsch C, Bacher U, Trümper L, Haase D, Schanz J.

Genes Chromosomes Cancer. 2015 Dec;54(12):809-17. doi: 10.1002/gcc.22292. Epub 2015 Sep 10.

PMID:
26355708
40.

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.

Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2091-2099. doi: 10.1016/j.bbmt.2015.07.028. Epub 2015 Aug 4.

41.

Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria.

Ayuk F, Veit R, Zabelina T, Bussmann L, Christopeit M, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander AR, Kröger N.

Ann Hematol. 2015 Oct;94(10):1727-32. doi: 10.1007/s00277-015-2452-6. Epub 2015 Jul 24.

PMID:
26204824
42.

Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML).

Pigneux A, Labopin M, Maertens J, Cordonnier C, Volin L, Socié G, Blaise D, Craddock C, Milpied N, Bacher U, Malard F, Esteve J, Nagler A, Mohty M; Acute Leukemia Working Party EBMT.

Leukemia. 2015 Dec;29(12):2375-81. doi: 10.1038/leu.2015.143. Epub 2015 Jun 17.

PMID:
26082270
43.

Hospital population screening reveals overrepresentation of CD5(-) monoclonal B-cell lymphocytosis and monoclonal gammopathy of undetermined significance of IgM type.

Voigtlaender M, Vogler B, Trepel M, Panse J, Jung R, Bokemeyer C, Bacher U, Binder M.

Ann Hematol. 2015 Sep;94(9):1559-65. doi: 10.1007/s00277-015-2409-9. Epub 2015 Jun 5.

PMID:
26040471
44.

Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation.

Mendorf A, Klyuchnikov E, Langebrake C, Rohde H, Ayuk F, Regier M, Christopeit M, Zabelina T, Bacher A, Stübig T, Wolschke C, Bacher U, Kröger N.

Acta Haematol. 2015;134(3):146-54. doi: 10.1159/000380757. Epub 2015 May 5.

PMID:
25968483
45.

Rare cytogenetic abnormalities in myelodysplastic syndromes.

Bacher U, Schanz J, Braulke F, Haase D.

Mediterr J Hematol Infect Dis. 2015 May 1;7(1):e2015034. doi: 10.4084/MJHID.2015.034. eCollection 2015. Review.

46.

Mutational profiling in patients with MDS: ready for every-day use in the clinic?

Bacher U, Kohlmann A, Haferlach T.

Best Pract Res Clin Haematol. 2015 Mar;28(1):32-42. doi: 10.1016/j.beha.2014.11.005. Epub 2014 Nov 12. Review.

PMID:
25659728
47.

The complex isotopologue space of glucose as a framework for the study of human intermediary metabolism.

Marsch S, Bacher A, Ettenhuber C, Gräwert T, Mückter H, Seidel D, Vogeser M, Laupitz R, Fischer M, Bacher U, Eisenreich W.

Isotopes Environ Health Stud. 2015;51(1):11-23. doi: 10.1080/10256016.2014.1001845. Epub 2015 Jan 26.

PMID:
25622148
48.

Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients.

Kern W, Bacher U, Haferlach C, Alpermann T, Schnittger S, Haferlach T.

Cytometry B Clin Cytom. 2015 May-Jun;88(3):154-64. doi: 10.1002/cyto.b.21224. Epub 2015 Mar 24.

49.

Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor.

Bachanova V, Burns LJ, Wang T, Carreras J, Gale RP, Wiernik PH, Ballen KK, Wirk B, Munker R, Rizzieri DA, Chen YB, Gibson J, Akpek G, Costa LJ, Kamble RT, Aljurf MD, Hsu JW, Cairo MS, Schouten HC, Bacher U, Savani BN, Wingard JR, Lazarus HM, Laport GG, Montoto S, Maloney DG, Smith SM, Brunstein C, Saber W.

Bone Marrow Transplant. 2015 Feb;50(2):197-203. doi: 10.1038/bmt.2014.259. Epub 2014 Nov 17.

50.

WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups.

Krauth MT, Alpermann T, Bacher U, Eder C, Dicker F, Ulke M, Kuznia S, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S.

Leukemia. 2015 Mar;29(3):660-7. doi: 10.1038/leu.2014.243. Epub 2014 Aug 11.

PMID:
25110071

Supplemental Content

Loading ...
Support Center